ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Pancreatic Cancer
Colorectal Cancer
Stomach Cancer
Esophageal Cancer
Prostatic Cancer

Adenocarcinoma trials near Paris, Île-de-France, FRA:

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...

Active, not recruiting
Gastric Cancer, Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: Ramucirumab
Drug: Paclitaxel

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Paris, France and 155 other locations

Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer (LOGICAN)

Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5-fluorouracile (5-FU) in frail patients with advanced, recurrent or metastatic...

Enrolling
Esophagus Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: Nivolumab
Drug: FOLFOX regimen

Phase 2

Unicancer
Unicancer

Paris, France and 28 other locations

Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma (LAP-NET1)

mFOLFIRINOX in the treatment of locally advanced pancreatic ductal adenocarcinoma.The study drug which is tested is the NP137 in association...

Enrolling
Pancreatic Ductal Adenocarcinoma
Drug: 5 FU
Drug: Irinotecan

Phase 1

Grenoble Alpes University Hospital Center (CHU)
Grenoble Alpes University Hospital Center (CHU)

Paris, France and 8 other locations

Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients (OPTIMIZE-1)

Phase 1b/2 study to assess the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Biological: CD40 agonist mitazalimab in combination with chemotherapy

Phase 1, Phase 2

Alligator Bioscience

Paris, France and 13 other locations

Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPAM)

TEDOPAM is a randomized (1.1.1) non-comparative phase II study. This study will assess the efficacy and safety of OSE2101 alone or in combination wit...

Enrolling
Pancreatic Ductal Adenocarcinoma
Metastatic Cancer
Drug: OSE2101
Drug: FOLFIRI

Phase 2

GERCOR - Multidisciplinary Oncology Cooperative Group

Paris, France and 27 other locations

Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Gastric adenocarcinoma is the 4th most frequent cancer and the 2nd leading cause of cancer mortality. Most of the patients have metastatic, ...

Active, not recruiting
Gastric Adenocarcinoma
Gastric Cancer
Drug: Durvalumab
Drug: Tremelimumab

Phase 2

Federation Francophone de Cancerologie Digestive

Paris, France and 34 other locations

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma (IMCODE003)

mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer tre...

Enrolling
Adenocarcinoma, Pancreatic Ductal
Drug: mFOLFIRINOX
Drug: Autogene cevumeran

Phase 2

Genentech
Genentech

Villejuif, France and 44 other locations

Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. (NEONIPIGA)

This is a non-randomized study, open label phase II study. The purpose of this study is to evaluate the complete pathologic response rate (cPRR) with...

Enrolling
MSI and or dMMR
Localized Oesogastric Adenocarcimona
Drug: Nivolumab 10 MG/ML
Drug: Ipilimumab 200 MG in 40 ML Injection

Phase 2

GERCOR - Multidisciplinary Oncology Cooperative Group

Paris, France and 14 other locations

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Active, not recruiting
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Drug: Domvanalimab
Drug: Zimberelimab

Phase 3

Arcus Biosciences
Arcus Biosciences

Villejuif, France and 203 other locations

A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer (ASPEN-06)

of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma...

Enrolling
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
Drug: Trastuzumab
Drug: Paclitaxel

Phase 2, Phase 3

ALX Oncology

Paris, France and 83 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems